VISCO (6782) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 視陽

VISCO (6782) reported revenue of NT$527.8 million for Oct 2026, +60.0% year on year and +6.6% from the previous month. Revenue for Jan–Oct 2026 was NT$4.47 billion (+28.6% year on year).

Revenue for Oct 2026 was a record high (previous high: Sep 2026, NT$495.2 million). →

Year-on-year revenue growth: 6 months in a row. →

In Oct 2026, it ranked No. 16 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$389.3 million24/10Nov 2024 NT$274.4 millionDec 2024 NT$245.9 millionJan 2025 NT$251.4 millionFeb 2025 NT$339.1 million25/02Mar 2025 NT$357.9 millionApr 2025 NT$403 millionMay 2025 NT$362.3 millionJun 2025 NT$308.9 million25/06Jul 2025 NT$397.3 millionAug 2025 NT$298.5 millionSep 2025 NT$431.1 millionOct 2025 NT$330 million25/10Nov 2025 NT$401.4 millionDec 2025 NT$337 millionJan 2026 NT$376.4 millionFeb 2026 NT$378.6 million26/02Mar 2026 NT$473.8 millionApr 2026 NT$371.3 millionMay 2026 NT$444.8 millionJun 2026 NT$450.9 million26/06Jul 2026 NT$465.7 millionAug 2026 NT$489.7 millionSep 2026 NT$495.2 millionOct 2026 NT$527.8 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$527.8 million+60.0%+6.6%
Sep 2026NT$495.2 million+14.9%+1.1%
Aug 2026NT$489.7 million+64.1%+5.2%
Jul 2026NT$465.7 million+17.2%+3.3%
Jun 2026NT$450.9 million+45.9%+1.4%
May 2026NT$444.8 million+22.8%+19.8%
Apr 2026NT$371.3 million-7.9%-21.6%
Mar 2026NT$473.8 million+32.4%+25.1%
Feb 2026NT$378.6 million+11.6%+0.6%
Jan 2026NT$376.4 million+49.8%+11.7%
Dec 2025NT$337 million+37.1%-16.0%
Nov 2025NT$401.4 million+46.3%+21.6%
Oct 2025NT$330 million-15.2%-23.5%
Sep 2025NT$431.1 million+39.1%+44.4%
Aug 2025NT$298.5 million-23.7%-24.9%
Jul 2025NT$397.3 million+19.7%+28.6%
Jun 2025NT$308.9 million-10.4%-14.7%
May 2025NT$362.3 million+22.1%-10.1%
Apr 2025NT$403 million+49.9%+12.6%
Mar 2025NT$357.9 million+42.5%+5.6%
Feb 2025NT$339.1 million+3.6%+34.9%
Jan 2025NT$251.4 million+6.4%+2.2%
Dec 2024NT$245.9 million-4.7%-10.4%
Nov 2024NT$274.4 million+33.0%-29.5%
Oct 2024NT$389.3 million+78.5%+25.6%

Jan–Oct 2026 cumulative: NT$4.47 billion (+28.6% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: VISCO vs PEC / VISCO vs Lotus Pharm / VISCO vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

主因客戶需求成長,使營收較去年同期增加逾50%。

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16